Novartis Access

watch video

Approximately 31 million people die each year from chronic non-communicable diseases (NCDs) in low– and middle–income countries, representing 80% of deaths from NCDs globally. The Novartis Access program makes available a portfolio of 15 critical chronic disease medicines to treat type 2 diabetes, cardiovascular diseases, respiratory illnesses, and breast cancer. These medicines are offered as a basket to governments, non-governmental organizations (NGOs) and other public-sector healthcare providers for USD 1 per treatment, per month. The aim is to make this innovative approach commercially sustainable over time, enabling continuous support in those regions.

In just two years, Novartis Access has delivered more than 800 000 monthly treatments in four countries, reaching almost 400 000 patients.

Beyond the medicines, Novartis Access offers capacity-building activities to support healthcare systems in preventing, diagnosing and treating NCDs.

Hon. James Macharia, Cabinet Secretary, Ministry of Health and Director of Medical Services of Kenya and Dr. Joerg Reinhardt, Chairman of the Board of Directors, Novartis, sign the memorandum of understanding at the launch event of Novartis Access, held at Kenyatta National Hospital in October 2015.

"Novartis strives to roll out the program in 30 countries in the coming years—depending on governmental and stakeholder deman."